Literature DB >> 11671443

Potentially Macrocyclic Peptidyl Boronic Acids as Chymotrypsin Inhibitors.

Zong-Qiang Tian1, Bradley B. Brown, David P. Mack, Craig A. Hutton, Paul A. Bartlett.   

Abstract

The possibility of forming a peptide boronate adduct in a serine protease active site that mimics the first tetrahedral intermediate in the peptide hydrolysis mechanism was explored with the complex boronic acid analogs 7, 8-OH, and 8-NH(2)(). In these structures, the P(1) and P(2) residues and the P(1)'-P(3)' residues are connected through the P(2) and P(1)' side chains, to encourage formation of the diester or amide-ester adducts via macrocyclization. These inhibitors were assembled from suitably protected derivatives of 2,4-diaminobutanoic acid or 2,4-diaminopentanoic acid (11), borophenylalanine (12), aspartic acid, malic acid or the substituted malic acid analog 13, and Leu-Arg dipeptide. Stereoselective syntheses were developed for the (S,S)-2,4-diaminopentanoate 11 and for the (S,S)-beta-isobutylmalate 13 derivatives. The complex peptidyl boronates 7 (K(i) = 26 nM) and 8-OH (68 nM) are potent inhibitors of alpha-chymotrypsin; however, the affinity of 7 is neither time- nor pH-dependent, and it is only moderately greater than that found for comparison compounds like 8-H (114 nM), 9 (356 nM), and 10 (219 nM) that cannot cyclize or form a diester adduct.

Entities:  

Year:  1997        PMID: 11671443     DOI: 10.1021/jo9615007

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  7 in total

1.  Design and Synthesis of 3,5-Disubstituted 1,2,4-Oxadiazole Containing Retinoids from a Retinoic Acid Receptor Agonist.

Authors:  Bhaskar C Das; Xiang-Ying Tang; Swarnava Sanyal; Seetaram Mohapatra; Patrick Rogler; Sabita Nayak; Todd Evans
Journal:  Tetrahedron Lett       Date:  2011-05-11       Impact factor: 2.415

2.  Inhibition of chymotrypsin by a complex of ortho-vanadate and benzohydroxamic acid: structure of the inert complex and its mechanistic interpretation.

Authors:  Aaron Moulin; Jason H Bell; R F Pratt; Dagmar Ringe
Journal:  Biochemistry       Date:  2007-05-01       Impact factor: 3.162

3.  Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin A-4 (CA-4) analogs.

Authors:  Bhaskar C Das; Xiang-Ying Tang; Patrick Rogler; Todd Evans
Journal:  Tetrahedron Lett       Date:  2012-08-01       Impact factor: 2.415

4.  Design and synthesis of boron containing potential pan-RAR inverse agonists.

Authors:  Bhaskar C Das; Xiang-Ying Tang; Todd Evans
Journal:  Tetrahedron Lett       Date:  2012-01-03       Impact factor: 2.415

5.  Design and synthesis of novel pinacolylboronate containing combretastatin 'antimitotic agent' analogues.

Authors:  Bhaskar C Das; Sakkarapalayam M Mahalingam; Todd Evans
Journal:  Tetrahedron Lett       Date:  2009-06-24       Impact factor: 2.415

6.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

Review 7.  The Boron Advantage: The Evolution and Diversification of Boron's Applications in Medicinal Chemistry.

Authors:  Katia Messner; Billy Vuong; Geoffrey K Tranmer
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.